SeaStar Medical Reports Positive Clinical Data for QUELIMMUNE Pediatric Therapy

Key Facts

1SeaStar Medical showcased new data from the QUELIMMUNE SAVE Registry at the AKI & CRRT 2026 conference.

2Results showed no device-related adverse events or immunosuppression in pediatric patients.

3The analysis confirmed continued strong survival data and a unique immunomodulatory mechanism for the SCD therapy.

SeaStar Medical (ICU) has presented encouraging new data from its SAVE Registry regarding the QUELIMMUNE Selective Cytopheretic Device (SCD) therapy. The findings, showcased at the AKI & CRRT 2026 conference, highlight the safety and efficacy of the treatment in pediatric patients. Notably, the analysis revealed no device-related adverse events or instances of immunosuppression among the study participants. The data further confirmed a strong survival rate and validated the unique immunomodulatory mechanism of the SCD therapy. This update reinforces the clinical viability of the company’s lead product in real-world applications. Investors view these results as a positive step toward broader commercial adoption in the medical device sector.